patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_801576 | REC_0015401 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 12.2 | 60 | male | 1 | 12 | 5.9 | 5 | pembrolizumab 200 mg q3w | 11.3 | true | MSI-H | 2026-03-15T05:36:01.223196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553780 | REC_0015402 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13 | 55 | male | 1 | 7 | 6.9 | 6 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:36:01.223644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837055 | REC_0015403 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 6.7 | 49 | male | 0 | 62 | 7.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:36:01.224128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963687 | REC_0015404 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 7.7 | 75 | male | 2 | 19 | 7.2 | 0 | sotorasib 960 mg daily | 31.9 | true | MSS | 2026-03-15T05:36:01.224588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853567 | REC_0015405 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 1.5 | 60 | female | 0 | 52 | 5.5 | 6 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:36:01.224971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317796 | REC_0015406 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 9.1 | 79 | female | 1 | 64 | 5.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:36:01.225494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756179 | REC_0015407 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 15 | 54 | male | 0 | 18 | 5.3 | 1 | sotorasib 960 mg daily | 28.1 | true | MSS | 2026-03-15T05:36:01.225874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385380 | REC_0015408 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10 | 83 | female | 1 | 13 | 5.7 | 6 | alectinib 600 mg BID | 7.7 | false | MSI-H | 2026-03-15T05:36:01.226249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739464 | REC_0015409 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 9.7 | 75 | male | 2 | 20 | 8.5 | 1 | osimertinib 80 mg daily | 20.9 | false | MSS | 2026-03-15T05:36:01.226632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805113 | REC_0015410 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 18.3 | 74 | female | 1 | 23 | 5.2 | 6 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:36:01.226999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488434 | REC_0015411 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.2 | 68 | female | 1 | 42 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.1 | false | MSS | 2026-03-15T05:36:01.227376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980159 | REC_0015412 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 18.5 | 44 | female | 0 | 12 | 3.8 | 8 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:01.227818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734955 | REC_0015413 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.9 | 72 | female | 2 | 7 | 7.1 | 5 | alectinib 600 mg BID | 18.8 | true | MSI-H | 2026-03-15T05:36:01.234420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790799 | REC_0015414 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.3 | 52 | male | 0 | 49 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.9 | false | MSS | 2026-03-15T05:36:01.234959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957877 | REC_0015415 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 13.7 | 72 | female | 1 | 11 | 5.1 | 1 | sotorasib 960 mg daily | 18.6 | false | MSS | 2026-03-15T05:36:01.235356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409975 | REC_0015416 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5 | 74 | female | 0 | 52 | 4.5 | 2 | pembrolizumab 200 mg q3w | 21.4 | true | MSS | 2026-03-15T05:36:01.235751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711394 | REC_0015417 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.4 | 60 | female | 1 | 18 | 7 | 6 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:01.238757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270400 | REC_0015418 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 12.2 | 76 | male | 2 | 14 | 4 | 5 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:36:01.239241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151530 | REC_0015419 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 9.2 | 69 | female | 1 | 1 | 7.3 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.239825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216825 | REC_0015420 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 9.1 | 74 | female | 2 | 4 | 3.8 | 7 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:01.240435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632778 | REC_0015421 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.8 | 66 | female | 0 | 18 | 7.5 | 0 | osimertinib 80 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:36:01.240903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757544 | REC_0015422 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.6 | 56 | female | 1 | 18 | 7.9 | 6 | alectinib 600 mg BID | 12.1 | true | MSS | 2026-03-15T05:36:01.241326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896053 | REC_0015423 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 9.2 | 53 | female | 0 | 42 | 6.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:36:01.241889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893296 | REC_0015424 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 9.8 | 66 | male | 1 | 8 | 3.4 | 5 | alectinib 600 mg BID | 8.1 | true | MSS | 2026-03-15T05:36:01.242350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691965 | REC_0015425 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 7.8 | 76 | female | 1 | 15 | 5.5 | 1 | entrectinib 600 mg daily | 25.6 | true | MSS | 2026-03-15T05:36:01.242748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208811 | REC_0015426 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.7 | 75 | male | 1 | 15 | 7.2 | 1 | sotorasib 960 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:01.243152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938081 | REC_0015427 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.5 | 61 | female | 0 | 18 | 5.9 | 6 | osimertinib 80 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:36:01.243519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681708 | REC_0015428 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.4 | 87 | female | 1 | 6 | 5.9 | 5 | alectinib 600 mg BID | 23 | true | MSS | 2026-03-15T05:36:01.243887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889521 | REC_0015429 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.6 | 68 | female | 0 | 53 | 8.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.6 | true | MSS | 2026-03-15T05:36:01.244357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963687 | REC_0015430 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 10.9 | 56 | female | 1 | 11 | 5.2 | 1 | osimertinib 80 mg daily | 13 | false | MSI-H | 2026-03-15T05:36:01.244761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368790 | REC_0015431 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 33 | 8.4 | 63 | male | 0 | 26 | 5.3 | 4 | pembrolizumab 200 mg q3w | 16.3 | true | MSS | 2026-03-15T05:36:01.245135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482639 | REC_0015432 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13 | 72 | female | 2 | 15 | 7.4 | 4 | sotorasib 960 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:36:01.245721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186500 | REC_0015433 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 16.9 | 64 | female | 0 | 8 | 6.3 | 4 | osimertinib 80 mg daily | 15 | false | MSS | 2026-03-15T05:36:01.246197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277920 | REC_0015434 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 18.4 | 65 | female | 0 | 11 | 4.7 | 2 | osimertinib 80 mg daily | 20.7 | true | MSS | 2026-03-15T05:36:01.246567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976911 | REC_0015435 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.8 | 76 | female | 3 | 10 | 3.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.1 | false | MSS | 2026-03-15T05:36:01.246938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841369 | REC_0015436 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.4 | 68 | female | 1 | 22 | 4.5 | 7 | alectinib 600 mg BID | 10.9 | false | MSI-H | 2026-03-15T05:36:01.247322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529295 | REC_0015437 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.7 | 56 | male | 1 | 9 | 4.9 | 3 | alectinib 600 mg BID | 14.6 | false | MSS | 2026-03-15T05:36:01.247677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939999 | REC_0015438 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.6 | 72 | female | 3 | 55 | 6.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:36:01.248021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456282 | REC_0015439 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 14.4 | 61 | female | 0 | 11 | 6.4 | 1 | sotorasib 960 mg daily | 21.1 | true | MSS | 2026-03-15T05:36:01.248630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918600 | REC_0015440 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.9 | 66 | male | 0 | 84 | 5.5 | 3 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:36:01.249058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690957 | REC_0015441 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 7.7 | 73 | female | 2 | 16 | 5.7 | 6 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:36:01.249460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570696 | REC_0015442 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.8 | 82 | female | 2 | 60 | 4.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 20.1 | false | MSS | 2026-03-15T05:36:01.249806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539618 | REC_0015443 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.5 | 66 | female | 0 | 83 | 4.1 | 2 | pembrolizumab 200 mg q3w | 26 | true | MSS | 2026-03-15T05:36:01.250154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474077 | REC_0015444 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 15.6 | 74 | female | 2 | 20 | 6.5 | 2 | entrectinib 600 mg daily | 19.3 | false | MSI-H | 2026-03-15T05:36:01.250526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765060 | REC_0015445 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.4 | 60 | female | 1 | 76 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.9 | false | MSS | 2026-03-15T05:36:01.251995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686918 | REC_0015446 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.9 | 72 | male | 2 | 23 | 4.4 | 5 | sotorasib 960 mg daily | 16 | false | MSS | 2026-03-15T05:36:01.252585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653496 | REC_0015447 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.3 | 74 | female | 1 | 14 | 4.8 | 8 | sotorasib 960 mg daily | 5.1 | false | MSS | 2026-03-15T05:36:01.253013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675971 | REC_0015448 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 17.3 | 63 | female | 1 | 8 | 5.3 | 0 | sotorasib 960 mg daily | 50.3 | false | MSI-H | 2026-03-15T05:36:01.253428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114879 | REC_0015449 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 13.8 | 52 | male | 0 | 16 | 4.8 | 5 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:01.253845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110895 | REC_0015450 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.8 | 67 | female | 0 | 16 | 7.9 | 5 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:01.254818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702634 | REC_0015451 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 2.5 | 68 | female | 0 | 29 | 2 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:36:01.255286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370300 | REC_0015452 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.3 | 60 | female | 0 | 23 | 6.1 | 2 | entrectinib 600 mg daily | 17.7 | false | MSS | 2026-03-15T05:36:01.257044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361532 | REC_0015453 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.8 | 87 | female | 1 | 13 | 3.5 | 9 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:36:01.257533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873379 | REC_0015454 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.8 | 65 | male | 1 | 20 | 4.8 | 6 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:01.257951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795326 | REC_0015455 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.7 | 82 | female | 2 | 10 | 5.3 | 5 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:36:01.258363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691568 | REC_0015456 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 32 | 13.3 | 68 | female | 1 | 16 | 5.3 | 0 | osimertinib 80 mg daily | 38.4 | true | MSI-H | 2026-03-15T05:36:01.258783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385469 | REC_0015457 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 12.6 | 72 | female | 1 | 16 | 4.3 | 2 | entrectinib 600 mg daily | 13.1 | false | MSS | 2026-03-15T05:36:01.259214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729266 | REC_0015458 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.4 | 69 | female | 1 | 14 | 7.5 | 5 | entrectinib 600 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:36:01.260067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794822 | REC_0015459 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.9 | 69 | female | 1 | 17 | 5.5 | 8 | osimertinib 80 mg daily | 8.4 | true | MSS | 2026-03-15T05:36:01.260596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655908 | REC_0015460 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 16.7 | 64 | female | 1 | 22 | 5.9 | 2 | alectinib 600 mg BID | 20.1 | true | MSI-H | 2026-03-15T05:36:01.261013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604039 | REC_0015461 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.6 | 47 | male | 0 | 48 | 7.2 | 6 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:36:01.261423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442012 | REC_0015462 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 14.8 | 67 | female | 0 | 23 | 5.4 | 4 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:36:01.261760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800008 | REC_0015463 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.4 | 68 | male | 1 | 14 | 6.8 | 6 | sotorasib 960 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:36:01.262091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843237 | REC_0015464 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.9 | 75 | female | 2 | 27 | 5.5 | 6 | osimertinib 80 mg daily | 5.4 | false | MSS | 2026-03-15T05:36:01.262418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581488 | REC_0015465 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 5.4 | 72 | female | 2 | 21 | 4.9 | 0 | osimertinib 80 mg daily | 36.7 | false | MSS | 2026-03-15T05:36:01.262724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142830 | REC_0015466 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 15.5 | 57 | male | 0 | 11 | 6.2 | 6 | pembrolizumab 200 mg q3w | 9.3 | true | MSS | 2026-03-15T05:36:01.263071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644419 | REC_0015467 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 25 | 2.9 | 70 | female | 2 | 21 | 3.6 | 0 | pembrolizumab 200 mg q3w | 33.8 | false | MSS | 2026-03-15T05:36:01.263441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789657 | REC_0015468 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 11.3 | 61 | male | 0 | 14 | 5.5 | 1 | alectinib 600 mg BID | 7.1 | false | MSS | 2026-03-15T05:36:01.263822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651834 | REC_0015469 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 18.3 | 74 | female | 0 | 25 | 4 | 1 | sotorasib 960 mg daily | 23.9 | false | MSI-H | 2026-03-15T05:36:01.264285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187100 | REC_0015470 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.1 | 77 | female | 1 | 14 | 4.7 | 6 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:01.267045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835376 | REC_0015471 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 18.7 | 65 | male | 1 | 22 | 3 | 2 | sotorasib 960 mg daily | 19.1 | false | MSS | 2026-03-15T05:36:01.267845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901668 | REC_0015472 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 9.1 | 72 | female | 2 | 0 | 7 | 1 | alectinib 600 mg BID | 21.4 | true | MSS | 2026-03-15T05:36:01.269142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695255 | REC_0015473 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14.3 | 78 | female | 1 | 14 | 6.7 | 5 | osimertinib 80 mg daily | 4.8 | false | MSI-H | 2026-03-15T05:36:01.269617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585568 | REC_0015474 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 2.3 | 67 | female | 0 | 14 | 4.4 | 0 | osimertinib 80 mg daily | 39.3 | false | MSS | 2026-03-15T05:36:01.270034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251836 | REC_0015475 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 10.9 | 81 | female | 2 | 17 | 5.6 | 4 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:36:01.270455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968068 | REC_0015476 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 10.5 | 68 | female | 1 | 18 | 3.7 | 2 | sotorasib 960 mg daily | 20.8 | true | MSI-H | 2026-03-15T05:36:01.270872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464656 | REC_0015477 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 28 | 6.2 | 79 | female | 2 | 58 | 6.3 | 0 | pembrolizumab 200 mg q3w | 24 | false | MSS | 2026-03-15T05:36:01.271975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938241 | REC_0015478 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.7 | 67 | female | 1 | 34 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.5 | false | MSS | 2026-03-15T05:36:01.273570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344676 | REC_0015479 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 21.3 | 86 | female | 1 | 22 | 4.7 | 1 | alectinib 600 mg BID | 19.9 | false | MSI-H | 2026-03-15T05:36:01.274172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720480 | REC_0015480 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 11.6 | 67 | female | 0 | 13 | 5.2 | 9 | osimertinib 80 mg daily | 7.7 | true | MSI-H | 2026-03-15T05:36:01.274607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430202 | REC_0015481 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.5 | 69 | female | 1 | 15 | 4.9 | 5 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:36:01.275013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446909 | REC_0015482 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 11.2 | 67 | male | 1 | 14 | 5.7 | 7 | osimertinib 80 mg daily | 9 | true | MSI-H | 2026-03-15T05:36:01.275439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580824 | REC_0015483 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 18.1 | 66 | female | 0 | 15 | 7 | 2 | sotorasib 960 mg daily | 31.5 | true | MSS | 2026-03-15T05:36:01.275814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971591 | REC_0015484 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 7.1 | 79 | male | 1 | 9 | 6.5 | 2 | entrectinib 600 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:01.276460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958621 | REC_0015485 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.8 | 56 | female | 0 | 23 | 7.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:36:01.276997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929336 | REC_0015486 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 15.9 | 69 | male | 0 | 20 | 6.3 | 2 | sotorasib 960 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:01.277756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235429 | REC_0015487 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13 | 81 | female | 2 | 20 | 3.2 | 4 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:36:01.278231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731245 | REC_0015488 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.5 | 76 | female | 0 | 16 | 5.7 | 8 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:36:01.278626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764730 | REC_0015489 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.7 | 57 | male | 0 | 45 | 2.5 | 8 | pembrolizumab 200 mg q3w | 15.2 | false | MSS | 2026-03-15T05:36:01.279023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960839 | REC_0015490 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 6.8 | 68 | female | 1 | 32 | 6.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 29.3 | true | MSS | 2026-03-15T05:36:01.279391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702355 | REC_0015491 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7.3 | 86 | female | 1 | 20 | 6.4 | 6 | entrectinib 600 mg daily | 11.8 | true | MSS | 2026-03-15T05:36:01.279788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660348 | REC_0015492 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 14.5 | 68 | female | 1 | 26 | 5.9 | 6 | sotorasib 960 mg daily | 6 | false | MSI-H | 2026-03-15T05:36:01.280280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885354 | REC_0015493 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 7.8 | 70 | female | 1 | 25 | 4.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:36:01.280703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242184 | REC_0015494 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 14.5 | 55 | male | 1 | 14 | 5.1 | 1 | sotorasib 960 mg daily | 14.4 | false | MSS | 2026-03-15T05:36:01.281137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862987 | REC_0015495 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 18.7 | 65 | female | 0 | 21 | 4.6 | 9 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:01.284317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449202 | REC_0015496 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 20.5 | 80 | male | 1 | 3 | 4.9 | 2 | entrectinib 600 mg daily | 27.7 | false | MSI-H | 2026-03-15T05:36:01.284815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281982 | REC_0015497 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.3 | 62 | female | 1 | 4 | 5.8 | 8 | osimertinib 80 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:36:01.286039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619096 | REC_0015498 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 16.2 | 50 | female | 0 | 5 | 5.8 | 6 | osimertinib 80 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:36:01.286520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478616 | REC_0015499 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 5.7 | 67 | female | 0 | 18 | 3.8 | 3 | alectinib 600 mg BID | 13.8 | true | MSS | 2026-03-15T05:36:01.286952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559470 | REC_0015500 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 15.9 | 73 | female | 1 | 12 | 7.8 | 2 | entrectinib 600 mg daily | 21.9 | false | MSS | 2026-03-15T05:36:01.287368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.